At a glance
ClinicalIndex Comparison RecordN/ACompleted· 164 enrolled
Drug / intervention
XADAGO (safinamide)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets
In Brief
An observational study evaluating XADAGO (safinamide) for Idiopathic Parkinson Disease. Completed, enrolled 164 participants across 30 sites.
Detailed Summary
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Parkinson Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedMay 2019
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedMay 10, 2019
Enrollment StartNov 30, 2017
Primary CompletionDec 23, 2019
Study CompletionJan 10, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.1 years ago
Interventions
XADAGO (safinamide)drug
XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.